Tags

Type your tag names separated by a space and hit enter

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Expert Opin Ther Targets. 2009 Jul; 13(7):743-51.EO

Abstract

OBJECTIVES

Non-HDL-cholesterol (non-HDL-C) and apolipoprotein (apo) B are proposed as treatment targets. The extent to which statin therapy affects relationships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes.

METHODS

Analyses were performed in 217 hypertriglyceridaemic type 2 diabetic patients (Diabetes Atorvastatin Lipid Intervention (DALI) cohort). 61 patients randomized to placebo, 70 to 10 mg atorvastatin daily and 65 - 80 mg atorvastin daily completed follow-up.

RESULTS

Baseline fasting LDL-C of 2.42 mmol/l and non-HDL-C of 3.69 mmol/l corresponded to the apoB guideline target of 0.90 g/l. During atorvastatin (10 and 80 mg daily), the LDL-C target was achieved most frequently, and lower LDL-C (2.38 and 2.29 mmol/l) and non-HDL-C (3.24 and 3.19 mmol/l) concentrations corresponded to this apoB goal. Decreases in LDL-C during atorvastatin treatment were negatively related (p < 0.001), but decreases in non-HDL-C were positively related to changes in triglycerides (p < 0.001), independently from decreases in apoB (p < 0.001 for all). Decreases in LDL-C and non-HDL-C were positively associated with decreases in cholesteryl ester transfer protein mass (p < 0.001).

CONCLUSIONS

During atorvastatin lower LDL-C and non-HDL-C levels correspond to the apoB guideline target, which would favour its use as treatment target.

Authors+Show Affiliations

University Medical Centre Groningen, Department of Endocrinology, P.O. Box 30001 9700 RB Groningen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19505224

Citation

Kappelle, Paul Jwh, et al. "Atorvastatin Affects Low Density Lipoprotein and Non-high Density Lipoprotein Cholesterol Relations With Apolipoprotein B in Type 2 Diabetes Mellitus: Modification By Triglycerides and Cholesteryl Ester Transfer Protein." Expert Opinion On Therapeutic Targets, vol. 13, no. 7, 2009, pp. 743-51.
Kappelle PJ, Zwang L, Huisman MV, et al. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opin Ther Targets. 2009;13(7):743-51.
Kappelle, P. J., Zwang, L., Huisman, M. V., Banga, J. D., Sluiter, W. J., Dallinga-Thie, G. M., & Dullaart, R. P. (2009). Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opinion On Therapeutic Targets, 13(7), 743-51. https://doi.org/10.1517/14728220903023866
Kappelle PJ, et al. Atorvastatin Affects Low Density Lipoprotein and Non-high Density Lipoprotein Cholesterol Relations With Apolipoprotein B in Type 2 Diabetes Mellitus: Modification By Triglycerides and Cholesteryl Ester Transfer Protein. Expert Opin Ther Targets. 2009;13(7):743-51. PubMed PMID: 19505224.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. AU - Kappelle,Paul Jwh, AU - Zwang,Louwerens, AU - Huisman,Menno V, AU - Banga,Jan Dirk, AU - Sluiter,Wim J, AU - Dallinga-Thie,Geesje M, AU - Dullaart,Robin Pf, PY - 2009/6/10/entrez PY - 2009/6/10/pubmed PY - 2009/8/26/medline SP - 743 EP - 51 JF - Expert opinion on therapeutic targets JO - Expert Opin Ther Targets VL - 13 IS - 7 N2 - OBJECTIVES: Non-HDL-cholesterol (non-HDL-C) and apolipoprotein (apo) B are proposed as treatment targets. The extent to which statin therapy affects relationships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes. METHODS: Analyses were performed in 217 hypertriglyceridaemic type 2 diabetic patients (Diabetes Atorvastatin Lipid Intervention (DALI) cohort). 61 patients randomized to placebo, 70 to 10 mg atorvastatin daily and 65 - 80 mg atorvastin daily completed follow-up. RESULTS: Baseline fasting LDL-C of 2.42 mmol/l and non-HDL-C of 3.69 mmol/l corresponded to the apoB guideline target of 0.90 g/l. During atorvastatin (10 and 80 mg daily), the LDL-C target was achieved most frequently, and lower LDL-C (2.38 and 2.29 mmol/l) and non-HDL-C (3.24 and 3.19 mmol/l) concentrations corresponded to this apoB goal. Decreases in LDL-C during atorvastatin treatment were negatively related (p < 0.001), but decreases in non-HDL-C were positively related to changes in triglycerides (p < 0.001), independently from decreases in apoB (p < 0.001 for all). Decreases in LDL-C and non-HDL-C were positively associated with decreases in cholesteryl ester transfer protein mass (p < 0.001). CONCLUSIONS: During atorvastatin lower LDL-C and non-HDL-C levels correspond to the apoB guideline target, which would favour its use as treatment target. SN - 1744-7631 UR - https://www.unboundmedicine.com/medline/citation/19505224/Atorvastatin_affects_low_density_lipoprotein_and_non_high_density_lipoprotein_cholesterol_relations_with_apolipoprotein_B_in_type_2_diabetes_mellitus:_modification_by_triglycerides_and_cholesteryl_ester_transfer_protein_ DB - PRIME DP - Unbound Medicine ER -